tradingkey.logo

Delcath Systems Inc

DCTH
8.640USD
0.000
Close 11/07, 16:00ETQuotes delayed by 15 min
305.07MMarket Cap
254.65P/E TTM

Delcath Systems Inc

8.640
0.000
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Delcath Systems Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Delcath Systems Inc's Score

Industry at a Glance

Industry Ranking
72 / 209
Overall Ranking
163 / 4614
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
23.143
Target Price
+167.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Delcath Systems Inc Highlights

StrengthsRisks
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1268.33% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 37.20M.
Overvalued
The company’s latest PE is 193.81, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 18.53M shares, decreasing 4.89% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 7.36K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 9.56, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 20.56M, representing a year-over-year increase of 83.60%, while its net profit experienced a year-over-year increase of 55.47%.

Score

Industry at a Glance

Previous score
9.56
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

10.00

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.81

Delcath Systems Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 4.70, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 193.81, which is 0.46% below the recent high of 194.71 and 120.84% above the recent low of -40.39.

Score

Industry at a Glance

Previous score
4.70
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 72/209
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.57, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Delcath Systems Inc is 22.00, with a high of 30.00 and a low of 18.00.

Score

Industry at a Glance

Previous score
8.57
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts
Buy
Current Rating
23.143
Target Price
+167.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Delcath Systems Inc
DCTH
7
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.76, which is lower than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 11.45 and the support level at 7.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.74
Change
0.02

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.385
Sell
RSI(14)
30.506
Neutral
STOCH(KDJ)(9,3,3)
14.533
Oversold
ATR(14)
0.628
High Vlolatility
CCI(14)
-128.587
Sell
Williams %R
90.312
Oversold
TRIX(12,20)
-0.782
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
8.912
Sell
MA10
9.365
Sell
MA20
10.290
Sell
MA50
10.743
Sell
MA100
11.173
Sell
MA200
12.684
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 52.97%, representing a quarter-over-quarter increase of 7.52%. The largest institutional shareholder is The Vanguard, holding a total of 1.61M shares, representing 4.60% of shares outstanding, with 24.29% increase in holdings.

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Rosalind Advisors, Inc.
3.30M
-3.31%
The Vanguard Group, Inc.
Star Investors
1.61M
+15.55%
BlackRock Institutional Trust Company, N.A.
1.56M
+821.60%
Deerfield Management Company, L.P.
812.56K
-0.07%
Citadel Advisors LLC
803.21K
+539.74%
Geode Capital Management, L.L.C.
703.17K
+128.10%
Vivo Capital, LLC
569.53K
-24.08%
Marshall Wace LLP
483.26K
--
State Street Investment Management (US)
473.89K
+316.63%
Oberweis Asset Management, Inc.
419.40K
+15.79%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 5.32, which is higher than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.32
Change
0
Beta vs S&P 500 index
0.42
VaR
--
240-Day Maximum Drawdown
+52.27%
240-Day Volatility
+73.62%

Return

Best Daily Return
60 days
+9.19%
120 days
--
5 years
--
Worst Daily Return
60 days
-9.00%
120 days
-100.00%
5 years
--
Sharpe Ratio
60 days
-1.71
120 days
--
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+52.27%
3 years
+71.73%
5 years
+90.55%
Return-to-Drawdown Ratio
240 days
-0.24
3 years
+0.65
5 years
-0.10
Skewness
240 days
--
3 years
--
5 years
--

Volatility

Realised Volatility
240 days
+73.62%
5 years
+84.11%
Standardised True Range
240 days
+8.61%
5 years
+6.20%
Downside Risk-Adjusted Return
120 days
--
240 days
--
Maximum Daily Upside Volatility
60 days
+41.53%
Maximum Daily Downside Volatility
60 days
+43.45%

Liquidity

Average Turnover Rate
60 days
+2.30%
120 days
+1.90%
5 years
--
Turnover Deviation
20 days
+71.70%
60 days
+63.22%
120 days
+34.87%

Peer Comparison

Healthcare Equipment & Supplies
Delcath Systems Inc
Delcath Systems Inc
DCTH
7.19 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI